Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax-based phase 1b/2 study in t(11;14) relapsed/refractory multiple myeloma
CTR20231932Phase 2Active
- Sponsor
- BeiGene
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax in multiple myeloma (MM), sponsored by BeiGene. Started Mar 2024; status: active.
02
Drugs
sonrotoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20231932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231932.